Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Alzheimer's disease drug development pipeline: 2022

Alzheimer's disease drug development pipeline: 2022 INTRODUCTIONAlzheimer's disease (AD) is increasing as the size of the aged population grows.1 In the United States there are currently 6.2 million individuals with AD dementia and the number will reach 12.7 million by 2050. In addition to those with AD in the dementia stages, there are ≈10 million individuals in the United States with mild cognitive impairment (MCI), half of whom (5 million) have MCI due to AD. The total number of persons in the United States with symptomatic forms of AD—MCI due to AD and AD dementia—is 11.2 million.1 The estimated 2021 cost of caring for those with Alzheimer's disease and related dementias (ADRD) was $355 billion. The world‐wide prevalence of AD dementia will triple from its current 50 to 150 million by 2050 with most of those affected living in low‐ and middle‐income countries.2The need for therapy to prevent, delay the onset, slow the progression, and improve the symptoms of AD is compelled by the rising number of those with AD and the growing public health crisis posed by the disease. Advances in therapy are being achieved; aducanumab, the first disease‐modifying therapy (DMT) to be approved for AD, became available on the market for those with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Alzheimer's & Dementia: Translational Research & Clinical Interventions Wiley

Alzheimer's disease drug development pipeline: 2022


Abstract

INTRODUCTIONAlzheimer's disease (AD) is increasing as the size of the aged population grows.1 In the United States there are currently 6.2 million individuals with AD dementia and the number will reach 12.7 million by 2050. In addition to those with AD in the dementia stages, there are ≈10 million individuals in the United States with mild cognitive impairment (MCI), half of whom (5 million) have MCI due to AD. The total number of persons in the United States with symptomatic forms of AD—MCI due to AD and AD dementia—is 11.2 million.1 The estimated 2021 cost of caring for those with Alzheimer's disease and related dementias (ADRD) was $355 billion. The world‐wide prevalence of AD dementia will triple from its current 50 to 150 million by 2050 with most of those affected living in low‐ and middle‐income countries.2The need for therapy to prevent, delay the onset, slow the progression, and improve the symptoms of AD is compelled by the rising number of those with AD and the growing public health crisis posed by the disease. Advances in therapy are being achieved; aducanumab, the first disease‐modifying therapy (DMT) to be approved for AD, became available on the market for those with

Loading next page...
 
/lp/wiley/alzheimer-s-disease-drug-development-pipeline-2022-rnSGYorWuP
Publisher
Wiley
Copyright
© 2022 the Alzheimer's Association
eISSN
2352-8737
DOI
10.1002/trc2.12295
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONAlzheimer's disease (AD) is increasing as the size of the aged population grows.1 In the United States there are currently 6.2 million individuals with AD dementia and the number will reach 12.7 million by 2050. In addition to those with AD in the dementia stages, there are ≈10 million individuals in the United States with mild cognitive impairment (MCI), half of whom (5 million) have MCI due to AD. The total number of persons in the United States with symptomatic forms of AD—MCI due to AD and AD dementia—is 11.2 million.1 The estimated 2021 cost of caring for those with Alzheimer's disease and related dementias (ADRD) was $355 billion. The world‐wide prevalence of AD dementia will triple from its current 50 to 150 million by 2050 with most of those affected living in low‐ and middle‐income countries.2The need for therapy to prevent, delay the onset, slow the progression, and improve the symptoms of AD is compelled by the rising number of those with AD and the growing public health crisis posed by the disease. Advances in therapy are being achieved; aducanumab, the first disease‐modifying therapy (DMT) to be approved for AD, became available on the market for those with

Journal

Alzheimer's & Dementia: Translational Research & Clinical InterventionsWiley

Published: Jan 1, 2022

Keywords: aducanumab; Alzheimer's disease; amyloid; biomarkers; clinical trials; Common Alzheimer's Disease Research Ontology (CADRO); donanemab; drug development; inflammation; lecanemab; pharmaceutical companies; repurposed drugs; tau

References